West Pharmaceutical Services reports Q2 2024 net sales of $702.1M, down 6.9%, and updates full-year guidance.
West Pharmaceutical Services announces Q2 2024 results with net sales of $702.1M (down 6.9%), organic net sales down 5.9%. Reported-diluted EPS at $1.51 vs $2.06 last year, adjusted-diluted EPS at $1.52 vs $2.11. Full-year 2024 net sales guidance updated to $2.870B-$2.900B from $3.000B-$3.025B, adjusted-diluted EPS to $7.50-$7.65 from $7.55-$7.65. A conference call is scheduled for 9 a.m. EDT.
July 25, 2024
3 Articles